News and Trends 30 Sep 2017 The Art of Darya Warner: Bacterial Portraits, Meaty Tomatoes and Bioluminescence From beautiful microscopic stills to designing the technology of the future, artist Darya Warner captures the beauty of life in her work. Darya Warner is an artist originally from Belarus, now based in the US, with an eye to spot beauty under the light of the microscope. From genetically engineered fluorescent E. coli to cauliflower, […] September 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 French Gene Therapy for Wilson’s Disease gets Orphan Status Vivet Therapeutics has been granted Orphan Drug Designation for its gene therapy for Wilson’s disease, VTX-801, by both the FDA and the European Commission. The French biotech Vivet Therapeutics is developing what could eventually become the first gene therapy for Wilson’s disease. Seeing its potential, both the FDA and the EC have decided to grant […] September 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 New British Spin-Out Wants to Replace Hormonal Menopause Treatment KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […] September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots Eligo Bioscience has announced its first fundraising round, amassing $20M (€18.5M) that will be put towards bringing it CRISPR nanobots to a first clinical trial in humans. The French startup Eligo Bioscience has grown rapidly since its foundation in 2014. The company has announced today its Series A round, which, led by Khosla Ventures and […] September 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2017 BioArt and Bacteria Exhibition is Coming to Oxford A new exhibition in Oxford features the beautiful art of Anna Dumitriu, exploring the complex world of microbes and how we interact with them. Anna Dumitriu, prolific bioartist that works with bacteria, will show some of her best work at the solo exhibition BioArt and Bacteria that will be hosted at the Museum of the […] September 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Sep 2017 New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […] September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2017 Biotech in Portugal gets a Boost with New Investment Fund Vesalius Biocapital and the Portuguese National Promotional Bank have announced a new joint venture that will invest in late-stage healthcare companies. The Instituição Financeira de Desenvolvimento (IFD), or Portuguese National Promotional Bank, is launching its first joint investment with an international VC, Vesalius Biocapital. Though its size hasn’t been revealed yet, the new fund is a 50/50 venture […] September 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 Update: After 25 years, MorphoSys Gets its First Antibody Approved Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […] September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 18 Sep 2017 David Chiswell: “We are getting close to the best way of making antibodies” We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […] September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2017 How Does it Feel Like to be a Slime Mold in Berlin? Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […] September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Swiss-US Partners Reveal New Candidate for Autoimmune Disease Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email